Response
Our study 1 aimed to provide evidence on whether the acute sympathoexcitation we found when hypertensive patients were exposed to a short-term drastic reduction in salt intake 2 could also be seen when salt intake was moderately reduced and maintained for a longer time. In the patients in whom the study requirements were met, this was clearly the case. It is worth noting that (1) we used perhaps the most sensitive and reproducible available technique to quantify sympathetic activity, (2) the protocol was extremely demanding because it required 4 good quality nerve recordings in each patient, and (3) although the study was not double-blind, bias was avoided because nerve traffic was quantified by an investigator unaware of the experimental design.
Furthermore, adherence to diet was assessed by 24h urinary sodium excretion before, during the dietary intervention (4 times), and after restoration of regular sodium diet. We cannot exclude that, despite instructions, some patients reduced caloric intake. However, a reduction in caloric intake and body weight leads to sympathetic deactivation. 3 Thus, its occurrence should have opposed rather than favored the sympathetic activation. Also, as when caused by antihypertensive drugs, sympathetic activation should be regarded as a non-desirable effect of the blood pressure lowering intervention on the basis of the evidence that increasing sympathetic activity may not only oppose the blood pressure reduction but also contribute to organ damage and metabolic alterations, some of which have been reported for low-sodium diet.
Our study did not aim to show to what extent a low-sodium diet is useful in hypertension, which is the reason why we avoided extensive quotation of the literature. We believe, however, that the issue remains somewhat controversial, 4 especially because morbidity and mortality data under low-salt diet are still unavailable. We do not agree that a low-sodium diet can be equated to diuretic treatment, whose mechanisms of action are more complex. Furthermore, this (as well as other treatment) fails to normalize the cardiovascular risk of the treated hypertensive patient, raising the possibility that some undesirable effects minimize the net benefit.
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